{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:46:42Z","timestamp":1790812002638,"version":"4.1.0"},"reference-count":90,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,3,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The central nervous system (CNS) is the most important site of extramedullary disease in adults with acute lymphoblastic leukemia (ALL). Although CNS disease is identified only in a minority of patients at the time of diagnosis, subsequent CNS relapses (either isolated or concurrent with other sites) occur in some patients even after the delivery of prophylactic therapy targeted to the CNS. Historically, prophylaxis against CNS disease has included intrathecal (IT) chemotherapy and radiotherapy (RT), although the latter is being used with decreasing frequency. Treatment of a CNS relapse usually involves intensive systemic therapy and cranial or craniospinal RT along with IT therapy and consideration of allogeneic hematopoietic cell transplant. However, short- and long-term toxicities can make these interventions prohibitively risky, particularly for older adults. As new antibody-based immunotherapy agents have been approved for relapsed\/refractory B-cell ALL, their use specifically for patients with CNS disease is an area of keen interest not only because of the potential for efficacy but also concerns of unique toxicity to the CNS. In this review, we discuss data-driven approaches for these common and challenging clinical scenarios as well as highlight how recent findings potentially support the use of novel immunotherapeutic strategies for CNS disease.<\/jats:p>","DOI":"10.1182\/blood.2022017035","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T16:36:43Z","timestamp":1671727003000},"page":"1379-1388","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":65,"title":["How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"141","author":[{"given":"Noam E.","family":"Kopmar","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington School of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, University of Washington School of Medicine, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2023103114512187100_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023103114512187100_bib2","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"24","key":"2023103114512187100_bib3","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2017.76.8192","article-title":"Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial","volume":"36","author":"Huguet","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023103114512187100_bib4","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A\u00a0pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2023103114512187100_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2005-11-4666","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993","volume":"108","author":"Lazarus","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2023103114512187100_bib6","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/sj.leu.2402006","article-title":"Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate\/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study","volume":"15","author":"Petersdorf","year":"2001","journal-title":"Leukemia"},{"issue":"2","key":"2023103114512187100_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.V55.2.199.199","article-title":"Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis","volume":"55","author":"Omura","year":"1980","journal-title":"Blood"},{"issue":"6","key":"2023103114512187100_bib8","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","article-title":"The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia","volume":"86","author":"Cortes","year":"1995","journal-title":"Blood"},{"issue":"11","key":"2023103114512187100_bib9","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.leukres.2008.04.011","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and\/or at first relapse: results from the GET-LALA group","volume":"32","author":"Reman","year":"2008","journal-title":"Leuk Res"},{"issue":"3","key":"2023103114512187100_bib10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2023103114512187100_bib11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cncr.10265","article-title":"Central nervous system relapse in adults with acute lymphoblastic leukemia","volume":"94","author":"Surapaneni","year":"2002","journal-title":"Cancer"},{"issue":"7716","key":"2023103114512187100_bib12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41586-018-0342-5","article-title":"Leukaemia hijacks a neural mechanism to invade the central nervous system","volume":"560","author":"Yao","year":"2018","journal-title":"Nature"},{"issue":"10","key":"2023103114512187100_bib13","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s43018-020-00115-2","article-title":"Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment is dependent on stearoyl CoA desaturase","volume":"1","author":"Savino","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"2023103114512187100_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10555-020-09848-z","article-title":"Involvement of the central nervous system\u00a0in acute lymphoblastic leukemia: opinions on molecular mechanisms and clinical implications based on recent data","volume":"39","author":"Lenk","year":"2020","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"2023103114512187100_bib15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.14411","article-title":"Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy","volume":"176","author":"Frishman-Levy","year":"2017","journal-title":"Br J Haematol"},{"issue":"7","key":"2023103114512187100_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41568-021-00355-z","article-title":"Leukaemia: a model metastatic disease","volume":"21","author":"Whiteley","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"2023103114512187100_bib17","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.leukres.2018.08.013","article-title":"Challenging \u201cprivileged\u201d stereotypes - leukemic blasts and the central nervous system","volume":"73","author":"Halsey","year":"2018","journal-title":"Leuk Res"},{"issue":"5","key":"2023103114512187100_bib18","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.V72.5.1784.1784","article-title":"Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia","volume":"72","author":"Kantarjian","year":"1988","journal-title":"Blood"},{"issue":"4","key":"2023103114512187100_bib19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.2020010438","article-title":"Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiation","volume":"138","author":"Tang","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2023103114512187100_bib20","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1182\/blood.V96.10.3381","article-title":"Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia","volume":"96","author":"Gajjar","year":"2000","journal-title":"Blood"},{"issue":"22","key":"2023103114512187100_bib21","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.2016.71.4774","article-title":"Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"35","author":"Winick","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023103114512187100_bib22","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/cncr.34073","article-title":"Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia","volume":"128","author":"Garcia","year":"2022","journal-title":"Cancer"},{"issue":"suppl 1","key":"2023103114512187100_bib23","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1182\/blood-2021-151653","article-title":"Can we lower the platelet threshold of \u2265 50\u00a0\u00d7 109\/L for performing a lumbar puncture safely in patients with hematological malignancies?","volume":"138","author":"Jordan","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2023103114512187100_bib24","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2021-151868","article-title":"Platelet transfusions prior to lumbar punctures, what is the evidence?","volume":"138","author":"Midha","year":"2021","journal-title":"Blood"},{"issue":"14","key":"2023103114512187100_bib25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1001\/jama.2020.14895","article-title":"Association of lumbar puncture with spinal hematoma in patients with and without coagulopathy","volume":"324","author":"Bodilsen","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"2023103114512187100_bib26","first-page":"328","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study","volume":"136","author":"Orvain","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2023103114512187100_bib27","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41375-019-0570-1","article-title":"Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study","volume":"34","author":"Thastrup","year":"2020","journal-title":"Leukemia"},{"issue":"13","key":"2023103114512187100_bib28","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1080\/10428194.2021.1957872","article-title":"Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry","volume":"62","author":"C\u00f3rdova-Serrano","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2023103114512187100_bib29","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00277-014-2080-6","article-title":"High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"93","author":"Del Principe","year":"2014","journal-title":"Ann Hematol"},{"issue":"20","key":"2023103114512187100_bib30","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"2023103114512187100_bib31","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children's Oncology Group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2023103114512187100_bib32","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023103114512187100_bib33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2006-06-027714","article-title":"Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia","volume":"109","author":"Moghrabi","year":"2007","journal-title":"Blood"},{"issue":"26","key":"2023103114512187100_bib34","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1056\/NEJMoa0900386","article-title":"Treating childhood acute lymphoblastic leukemia without cranial irradiation","volume":"360","author":"Pui","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023103114512187100_bib35","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3324\/haematol.2014.123273","article-title":"Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia","volume":"100","author":"Bassan","year":"2015","journal-title":"Haematologica"},{"issue":"23","key":"2023103114512187100_bib36","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1200\/JCO.19.02892","article-title":"Impact of Intrathecal triple therapy versus intrathecal methotrexate on disease-free survival for high-risk B-lymphoblastic leukemia: Children's Oncology Group study AALL1131","volume":"38","author":"Salzer","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023103114512187100_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/pbc.24228","article-title":"Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia","volume":"60","author":"Richards","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2023103114512187100_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/10428194.2017.1326597","article-title":"Managing CNS disease in adults with acute lymphoblastic leukemia","volume":"59","author":"Larson","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023103114512187100_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2018.05.067","article-title":"Radiation in central nervous system leukemia: guidelines from the International Lymphoma Radiation Oncology Group","volume":"102","author":"Pinnix","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"2023103114512187100_bib40","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"2023103114512187100_bib41","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/bloodadvances.2021004813","article-title":"Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL","volume":"5","author":"Wieduwilt","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"2023103114512187100_bib42","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(03)01050-7","article-title":"Gleevec does not cross blood-brain barrier","volume":"4","author":"Senior","year":"2003","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023103114512187100_bib43","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2023103114512187100_bib44","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"2023103114512187100_bib45","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1080\/10428194.2021.1894647","article-title":"Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice","volume":"62","author":"Ravi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"2023103114512187100_bib46","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"2023103114512187100_bib47","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"2023103114512187100_bib48","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"2023103114512187100_bib49","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgme.2018.05.003","article-title":"Best practices for the use of intracerebroventricular drug delivery devices","volume":"124","author":"Slavc","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2023103114512187100_bib50","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s40272-018-0298-9","article-title":"The use of Ommaya reservoirs to deliver central nervous system-directed chemotherapy in childhood acute lymphoblastic leukaemia","volume":"20","author":"Wilson","year":"2018","journal-title":"Paediatr Drugs"},{"issue":"4","key":"2023103114512187100_bib51","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00043426-200205000-00011","article-title":"Intrathecal thiotepa: reappraisal of an established therapy","volume":"24","author":"Fisher","year":"2002","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"3","key":"2023103114512187100_bib52","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/pbc.23317","article-title":"Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962)","volume":"58","author":"Potter","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2023103114512187100_bib53","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/MPH.0000000000000642","article-title":"Efficacy and toxicity of intrathecal liposomal cytarabine in first-line therapy of childhood acute lymphoblastic leukemia","volume":"38","author":"Levinsen","year":"2016","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"issue":"8","key":"2023103114512187100_bib54","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","article-title":"Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2023103114512187100_bib55","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1365-2141.2008.07497.x","article-title":"Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy","volume":"144","author":"Jaime-P\u00e9rez","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"2023103114512187100_bib56","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/ajh.24329","article-title":"Safety and efficacy of intrathecal rituximab\u00a0in children with B cell lymphoid CD20+ malignancies: an international retrospective study","volume":"91","author":"Ceppi","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2023103114512187100_bib57","first-page":"669","article-title":"Vincristine minibag administration: a quality improvement project to minimize medical errors","volume":"22","author":"Beaver","year":"2018","journal-title":"Clin J Oncol Nurs"},{"issue":"8","key":"2023103114512187100_bib58","first-page":"464","article-title":"Death and neurological devastation from intrathecal vinca alkaloids","volume":"41","author":"Grissinger","year":"2016","journal-title":"P\u00a0T"},{"issue":"3","key":"2023103114512187100_bib59","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3171\/spi.2007.6.3.280","article-title":"Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report","volume":"6","author":"Qweider","year":"2007","journal-title":"J\u00a0Neurosurg Spine"},{"issue":"24","key":"2023103114512187100_bib60","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2023103114512187100_bib61","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","article-title":"Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial","volume":"100","author":"Dombret","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2023103114512187100_bib62","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv"},{"issue":"20","key":"2023103114512187100_bib63","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2023103114512187100_bib64","first-page":"1060","article-title":"Hematopoietic cell transplantation in acute lymphoblastic leukemia: better long term event-free survival with conditioning regimens containing total body irradiation","volume":"85","author":"Granados","year":"2000","journal-title":"Haematologica"},{"issue":"3","key":"2023103114512187100_bib65","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2023103114512187100_bib66","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/leu.2013.253","article-title":"Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease","volume":"28","author":"Bachanova","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"2023103114512187100_bib67","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3109\/10428194.2016.1160080","article-title":"Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia","volume":"57","author":"Cassaday","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023103114512187100_bib68","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.2019.237230","article-title":"Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433","volume":"106","author":"Lew","year":"2021","journal-title":"Haematologica"},{"issue":"19","key":"2023103114512187100_bib69","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.2005.03.3373","article-title":"Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study","volume":"24","author":"Barredo","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023103114512187100_bib70","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1200\/JCO.1999.17.12.3745","article-title":"Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study","volume":"17","author":"Ritchey","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"9757","key":"2023103114512187100_bib71","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1016\/S0140-6736(10)62002-8","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"2023103114512187100_bib72","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2023103114512187100_bib73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.prro.2016.06.008","article-title":"Low-dose cranial boost in high-risk adult acute lymphoblastic leukemia patients undergoing bone marrow transplant","volume":"7","author":"Su","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2023103114512187100_bib74","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.prro.2018.12.005","article-title":"The impact of low-dose cranial boost on the long-term outcomes of adult patients with high-risk acute lymphoblastic leukemia undergoing total body irradiation and allogeneic hematopoietic stem cell transplantation","volume":"9","author":"Famoso","year":"2019","journal-title":"Pract Radiat Oncol"},{"issue":"6","key":"2023103114512187100_bib75","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.bbmt.2008.03.011","article-title":"Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system","volume":"14","author":"Harker-Murray","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023103114512187100_bib76","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.bbmt.2015.10.016","article-title":"Implications and management of central nervous system involvement before allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia","volume":"22","author":"Aldoss","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2023103114512187100_bib77","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.bbmt.2014.07.005","article-title":"Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation","volume":"20","author":"Hamdi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023103114512187100_bib78","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.bbmt.2018.12.757","article-title":"ASBMT statement on routine prophylaxis for central nervous system recurrence of acute lymphoblastic leukemia following allogeneic hematopoietic cell transplantation","volume":"25","author":"Sauter","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2023103114512187100_bib79","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023103114512187100_bib80","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023103114512187100_bib81","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"10299","key":"2023103114512187100_bib82","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"2023103114512187100_bib83","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase ii, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023103114512187100_bib84","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2018-99-117400","article-title":"Safety and efficacy of blinatumomab in patients with central nervous system (CNS) disease: a single institution experience","volume":"132","author":"Alfayez","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2023103114512187100_bib85","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"2023103114512187100_bib86","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023103114512187100_bib87","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/j.bbmt.2020.07.036","article-title":"Chimeric antigen receptor T cell therapy in patients with multiply relapsed or refractory extramedullary leukemia","volume":"26","author":"Rubinstein","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2023103114512187100_bib88","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023103114512187100_bib89","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/cncr.33967","article-title":"Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia","volume":"128","author":"Aldoss","year":"2022","journal-title":"Cancer"},{"issue":"15","key":"2023103114512187100_bib90","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/cncr.28136","article-title":"Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia","volume":"119","author":"Kantarjian","year":"2013","journal-title":"Cancer"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/12\/1379\/2086776\/blood_bld-2022-017035-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/12\/1379\/2086776\/blood_bld-2022-017035-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T10:52:37Z","timestamp":1698749557000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/12\/1379\/493851\/How-I-prevent-and-treat-central-nervous-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":90,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,3,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022017035","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}